Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02716428 · ClinicalTrials.gov registry record · Phase 2
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
A Phase 2 study of Chronic Hepatitis C and Hepatitis C (HCV), sponsored by Trek Therapeutics, PBC.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 6
- Study locations
NCT02716428: Completed Phase 2 study of Chronic Hepatitis C and Hepatitis C (HCV), sponsored by Trek Therapeutics, PBC.
NCT02716428 is a Phase 2 study of Chronic Hepatitis C and Hepatitis C (HCV) that has completed, run by Trek Therapeutics, PBC. The registered enrollment target is 25 participants, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (88% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02716428, a Phase 2 study of Chronic Hepatitis C and Hepatitis C (HCV), has completed, sponsored by Trek Therapeutics, PBC.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 6
- Study locations
Study Summary
Phase 2 study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 alone or in combination with other antivirals for a 12-week treatment duration in treatment-naïve participants with genotype 1b hepatitis C virus (HCV) infection.
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG TD-6450
- DRUG Faldaprevir
Study Locations (6)
Other
- Auckland Clinical Studies - Auckland
- Dunedin Hospital - Dunedin
- Waikato Hospital - Waikato
California
- Southern California Research Center - Coronado
Florida
- Bach and Godofsky Infectious Diseases - Bradenton
Tennessee
- Gastro One - Germantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-09 |
| Phase | Phase 2 |
What the finished NCT02716428 record still lists
NCT02716428 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (88% lower).
The record links to 4 conditions, with Chronic Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which Ribavirin is the first listed.
NCT02716428 lists 6 locations in 4 states (Other, California, Florida).
Frequently Asked Questions
What is clinical trial NCT02716428 about?
NCT02716428 is a clinical study titled "A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection". Phase 2 study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 alone or in combination with other antivirals for a 12-week treatment duration in treatment-naïve participants with genotype 1b hepatitis C virus (HCV) infection.
What is the current status of trial NCT02716428?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2016-05. Estimated completion is 2017-09.
What conditions does trial NCT02716428 study?
This clinical trial studies the following conditions: Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Viral Infection, Hepatitis C Genotype 1.
What interventions are being tested in trial NCT02716428?
The interventions under investigation include: Ribavirin (DRUG), TD-6450 (DRUG), Faldaprevir (DRUG).
Who is sponsoring clinical trial NCT02716428?
This trial is sponsored by Trek Therapeutics, PBC, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02716428 being conducted?
This trial has 6 study locations across California, Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02716428's enrollment target sits among peer trials
25 13th of 16 higher than 4 of 16 other Chronic Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
COMPLETED · Phase 2
-
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
COMPLETED · Phase 2
-
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
COMPLETED · Phase 2
-
Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment
COMPLETED · Phase 2
-
Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
COMPLETED · Phase 2
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia